老年人中皮质类固醇诱导的糖尿病风险的量化
Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly.
作者信息
Blackburn David, Hux Janet, Mamdani Muhammad
机构信息
University of Toronto Faculty of Pharmacy, Ontario, Canada.
出版信息
J Gen Intern Med. 2002 Sep;17(9):717-20. doi: 10.1046/j.1525-1497.2002.10649.x.
Abstract
We conducted a population-based cohort study using administrative databases to quantify the association between oral and inhaled corticosteroid use and onset of diabetes mellitus in the elderly. Proton pump inhibitor (PPI) users were used as a control group. Relative to PPI users (N = 53,845), oral corticosteroid users (N = 31,864) were more likely to develop diabetes (adjusted rate ratio [aRR], 2.31; 95% confidence interval [95% CI], 2.11 to 2.54); however, inhaled corticosteroid users (N = 38,441) were not (aRR, 1.03; 95% CI, 0.93 to 1.14). The estimated number needed to harm for continuous use of oral corticosteroids relative to PPIs over 1, 2, and 3 years of use were 41, 23, and 16, respectively.
摘要
我们利用行政数据库开展了一项基于人群的队列研究，以量化老年人口服和吸入皮质类固醇使用与糖尿病发病之间的关联。使用质子泵抑制剂（PPI）的人群作为对照组。与PPI使用者（N = 53,845）相比，口服皮质类固醇使用者（N = 31,864）患糖尿病的可能性更高（调整率比[aRR]为2.31；95%置信区间[95%CI]为2.11至2.54）；然而，吸入皮质类固醇使用者（N = 38,441）并非如此（aRR为1.03；95%CI为0.93至1.14）。相对于PPI，连续使用口服皮质类固醇1年、2年和3年的估计伤害所需人数分别为41、23和16。
相似文献
1
Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly.
J Gen Intern Med. 2002 Sep;17(9):717-20. doi: 10.1046/j.1525-1497.2002.10649.x.
2
Use of inhaled and oral corticosteroids and the long-term risk of cataract.
Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25.
3
Inhaled corticosteroids and the risk of diabetes among the elderly.
Br J Clin Pharmacol. 2002 Jul;54(1):59-64. doi: 10.1046/j.1365-2125.2002.01610.x.
4
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
J Am Med Dir Assoc. 2004 Jan-Feb;5(1):38-46.
5
Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy.
Ann Palliat Med. 2015 Apr;4(2):70-7. doi: 10.3978/j.issn.2224-5820.2015.04.07.
6
Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients.
Acta Med Iran. 2017 Jun;55(6):375-380.
7
The Risk of Sepsis with Inhaled and Oral Corticosteroids in Patients with COPD.
COPD. 2017 Apr;14(2):137-142. doi: 10.1080/15412555.2016.1238450. Epub 2016 Dec 23.
8
Use of inhaled corticosteroids and risk of fractures.
J Bone Miner Res. 2001 Mar;16(3):581-8. doi: 10.1359/jbmr.2001.16.3.581.
9
The relationship between proton pump inhibitor adherence and fracture risk in the elderly.
Calcif Tissue Int. 2014 Jun;94(6):597-607. doi: 10.1007/s00223-014-9855-6. Epub 2014 Apr 6.
10
Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Int J Cardiol. 2014 Nov 15;177(1):292-7. doi: 10.1016/j.ijcard.2014.09.036. Epub 2014 Sep 28.
引用本文的文献
1
Current Review of Comorbidities in Chronic Rhinosinusitis.
Curr Allergy Asthma Rep. 2024 Nov 19;25(1):4. doi: 10.1007/s11882-024-01184-4.
2
Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study.
RMD Open. 2024 Apr 30;10(2):e004246. doi: 10.1136/rmdopen-2024-004246.
3
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem.
Endocrinol Metab (Seoul). 2024 Apr;39(2):222-238. doi: 10.3803/EnM.2024.1951. Epub 2024 Mar 27.
4
Prevalence of Steroid-Induced Hyperglycemia in King Abdulaziz Specialist Hospital, Taif City, Saudi Arabia.
Cureus. 2024 Feb 18;16(2):e54430. doi: 10.7759/cureus.54430. eCollection 2024 Feb.
5
Association and Mechanisms of Proton Pump Inhibitors Use with Type-2Diabetes Mellitus Incidence in Adults: A Systemic Review andMeta-Analysis.
Curr Diabetes Rev. 2024;20(10):e120124225581. doi: 10.2174/0115733998254869231101095222.
6
Toxicity evaluation of synthetic glucocorticoids against breast cancer cell lines MDA-MB-231, MCF-7 and human embryonic kidney HEK293.
Med Oncol. 2023 Sep 29;40(11):309. doi: 10.1007/s12032-023-02189-1.
7
Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review.
World J Diabetes. 2023 Aug 15;14(8):1202-1211. doi: 10.4239/wjd.v14.i8.1202.
8
Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit.
Curr Drug Saf. 2024;19(3):332-341. doi: 10.2174/1574886318666230816090606.
9
Microbiota-dependent and -independent effects of obesity on transplant rejection and hyperglycemia.
Am J Transplant. 2023 Oct;23(10):1526-1535. doi: 10.1016/j.ajt.2023.06.011. Epub 2023 Jun 23.
10
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016.
本文引用的文献
1
When should hypertension be treated? The different perspectives of Canadian family physicians and patients.
CMAJ. 2000 Aug 22;163(4):403-8.
2
Deteriorating diabetic control associated with high-dose inhaled budesonide.
Eur Respir J. 1999 Jul;14(1):242-3. doi: 10.1183/09031936.99.141.
3
High dose inhaled corticosteroids and dose dependent loss of diabetic control.
BMJ. 1998 Nov 28;317(7171):1491. doi: 10.1136/bmj.317.7171.1491.
4
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.
J Clin Invest. 1997 Oct 15;100(8):2094-8. doi: 10.1172/JCI119743.
5
Post-transplant diabetes mellitus. The role of immunosuppression.
Drug Saf. 1997 Apr;16(4):242-57. doi: 10.2165/00002018-199716040-00002.
6
Information needed to decide about cardiovascular treatment in primary care.
BMJ. 1997 Jan 25;314(7076):277-80. doi: 10.1136/bmj.314.7076.277.
7
Incidence and prevalence of diabetes in Manitoba, 1986-1991.
Diabetes Care. 1996 Aug;19(8):807-11. doi: 10.2337/diacare.19.8.807.
8
Glucocorticoids and the risk for initiation of hypoglycemic therapy.
Arch Intern Med. 1994 Jan 10;154(1):97-101.
9
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy.
J Intern Med. 1994 Dec;236(6):619-32. doi: 10.1111/j.1365-2796.1994.tb00855.x.
10
Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?
Med Decis Making. 1995 Apr-Jun;15(2):152-7. doi: 10.1177/0272989X9501500208.
Zotero 插件